Diametric Capital’s Orchestra BioMed OBIO Stock Holding History

Diametric Capital’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-18,919	Closed	-$80.4K	–	622
2026 Q1	$80.4K	Buy	+18,919	New	+$80.5K	0.02%	431

Other funds holding OBIO

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Diametric Capital's OBIO Position: Q2 2026 in Review

Diametric Capital sold out of Orchestra BioMed (OBIO) in Q2 2026, closing a stake of 18,919 shares — an estimated $80.4K sold.

Diametric Capital first reported a position in OBIO in Q1 2026 and held it in 1 quarter. The position peaked at $80.4K in Q1 2026. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

Diametric Capital reported no remaining Orchestra BioMed position as of Q2 2026 after selling out during the quarter.
Diametric Capital sold 18,919 Orchestra BioMed shares in Q2 2026, an estimated $80.4K.
Diametric Capital first reported a position in Orchestra BioMed in Q1 2026 and held it in 1 quarter.
Diametric Capital's Orchestra BioMed position peaked at $80.4K in Q1 2026.
77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Diametric Capital's 13F filing for Q2 2026, filed 14 Aug 2026.